Asteroid structure-specific endonuclease 1 frameshift peptide (ASTE1 FSP)

The frameshift peptide antigen derived from HT001 (ASTE1) mutations is a tumor-specific neoantigen generated by a -1 base pair deletion in the coding microsatellite of the Asteroid structure-specific endonuclease 1 (ASTE1) gene (NCI Drug Dictionary; AACR Journals). This mutation is a hallmark of microsatellite instability-high (MSI-H) cancers, which occur in approximately 15% of colorectal, gastric, and endometrial tumors and are characteristic of Lynch syndrome (NIH; BMJ). The resulting frameshift creates a novel, immunogenic C-terminal peptide sequence that is absent in normal cells, providing a highly specific target for the immune system (Frontiers in Immunology; AACR Journals). Therapeutic strategies, such as the Micoryx vaccine, utilize these shared frameshift peptides to induce a robust T-cell and antibody-mediated immune response against MSI-H tumor cells (AACR Journals; ResearchGate). Because these mutations are recurrent and shared across many patients, they serve as "off-the-shelf" neoantigen targets for cancer immunotherapy and prevention (Frontiers in Immunology; BMJ). Clinical trials have shown that vaccination with these peptides is well-tolerated and can effectively prime the immune system to recognize and attack malignant cells expressing the mutated protein (AACR Journals; BMJ).

Other names

HT001 frameshift peptideASTE1 frameshift peptideHT001(-1) FSPAsteroid homolog 1 frameshift peptideHT001 mutation-derived antigenASTE1-1 frameshift peptide

Induction of tumor-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against cells expressing the frameshifted ASTE1 protein.